Filing Flows › Comparisons › INVU vs CJMB
Investview vs Callan JMB: INVU and CJMB compared
Investview is the larger company: $2.5M of revenue in its latest quarter (Q2 2026) against $1.4M for Callan JMB (Q2 2026). Callan JMB is growing faster (-17% against -73% a year earlier). Investview is more profitable, with an operating margin of -83.2% against -97.8%.
Where the money goes: INVU and CJMB
Investview (INVU) · Q2 2026
Investview, Q2 2026: revenue $2.5M (-73% year over year), operating margin -83.2%, net loss $3.2M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
Callan JMB (CJMB) · Q2 2026
Callan JMB, Q2 2026: revenue $1.4M (-17% year over year), operating margin -97.8%, net loss $1.2M, operating cash flow −$396K. The chart follows the revenue to costs, profit and cash.
| Investview (INVU) | Callan JMB (CJMB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $2.5M | $1.4M |
| Revenue growth, Y/Y | -73% | -17% |
| Operating margin | -83.2% | -97.8% |
| Net earnings | −$3.2M | −$1.2M |
| Net margin | -129.9% | -89.5% |
| Operating cash flow | −$2.8M | −$396K |
Where the revenue comes from
Investview
- Membership Revenue: $2.1M (85%)
- Health and Wellness Revenue: $243K (10%)
- Coffee Sales: $132K (5%)
- Other: $2K (0%)
Callan JMB
- Emergency Preparedness: $1.0M (76%)
- Specialty Packaging: $328K (24%)
Questions
Which is bigger, Investview or Callan JMB?
Investview is the larger company: $2.5M of revenue in its latest quarter (Q2 2026) against $1.4M for Callan JMB (Q2 2026).
Is Investview or Callan JMB growing faster?
Callan JMB is growing faster (-17% against -73% a year earlier).
Which is more profitable, Investview or Callan JMB?
Investview is more profitable, with an operating margin of -83.2% against -97.8%.
More: Investview earnings · how Investview makes money · Callan JMB earnings · how Callan JMB makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.